Undervalued Medical Stocks
Small Cap Stocks to Buy
Money Info Show
Replay of the Show Part 1:
Replay of the Show Part 2 with live interview:
The show featured a live interview with
Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
(NASDAQ Stock Symbol: CBLI)
Corporate Site: http://www.cbiolabs.com
Developing and commercializing
innovative drugs to
treat cancer and orphan diseases and
protect healthy tissues.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need.
The company’s lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate.
CBL0137 is under development by Incuron, LLC, a Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund “Bioprocess Capital Ventures,” and Cleveland BioLabs.
Cleveland BioLabs, Inc. conducts business in the United States and in the Russian Federation through its wholly and majority owned operating subsidiaries.
The company maintains strategicrelationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children’s Cancer Institute Australia for Medical Research.
To learn more about Cleveland BioLabs, Inc.
visit the Company’s website at CBIOLabs.com.
To learn more about Incuron, LLC
visit the company’s website at Incuron.com.
See more at Yahoo Finance Small Cap Medical Stock News
Medical Stocks In The News
Cleveland BioLabs Reduces Debt With $3.5 Million At-the-Market Private Placement of Unregistered Stock
(Marketwired – Jun 18, 2014) – Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it entered into a securities purchase agreement (the “Purchase Agreement”) with Dr. Mikhail Mogutov, Chairman of the Board of Directors of Incuron, LLC and Chairman of the Investment Committee and founder of Bioprocess Capital Ventures and one institutional investor (the “Investors”), to issue and sell in a private placement $3.5 million worth of the Company’s common stock, par value $.005 per share (the “Common Stock”),and warrants to purchase Common Stock.
Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, “This transaction deepens our strategic relationship with Dr. Mogutov. We appreciate his continued support of our science and development pipeline. These proceeds enable us to reduce the debt on our balance sheet by two-thirds, favorably impacting our cash runway.”
The Princeton Research Money Info show features where to invest now, stock market, business, economy and financial investment news.
Money Info is hosted by Mike King and Charles Moskowitz.